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Abstract: 
Purpose  The aim of this study was to evaluate health-related quality of life (HRQOL) in 
women and men undergoing radiation treatment for head and neck cancer through the 
intervention period and examine if  age, body mass index (BMI) and smoking status at 
baseline may modify changes in HRQOL.   
Methods  HRQOL was examined by the European Organization for Research and Treatment 
of Cancer (EORTC) QLQ-C30 and the EORTC QLQ-H&N35, in the beginning and end of 
the treatment period in 65 patients at the University Hospital in Northern Norway. Changes in 
HRQOL were calculated and compared by paired sample T-tests. Linear multiple regression 
analyses were used to examine if baseline characteristics had any influence HRQOL changes. 
Results  Most aspects of HRQOL declined substantially and significantly (p<0.001) with a 
magnitude of more than one standard deviation during the radiation treatment period 
irrespective of sex and age. Smoking status at baseline had some, albeit minor, influence on 
changes in HRQOL. Patients who continued smoking during therapy had significantly higher 
decline in several aspects of HRQOL, compared to patients who stopped smoking.  
Conclusions  HRQOL decline with substantial magnitude in patients undergoing radiation 
treatment for head and neck cancer, but smoking cessation may modify the declining quality 
of life.  
 
Introduction 
Treatments of head and neck (H&N) cancer include surgery, radiotherapy (RT), 
chemotherapy, target therapy or a combination of these modalities. The diagnosis and the 
following treatment may exert a severe impact on patient’s quality of life (QOL) (So et al., 
2012). The malignancy affects the most visible area of the body, and may influence the most 
fundamental activities of daily life in a negative way, such as speech, breathing, eating and 
drinking (Larsson and Hedelin, 2003; Wells 1998). H&N cancer patients' illness often 
involves physical symptoms, psychological distress, as well as side effects from RT (Archer 
et al., 2008). The treatment can result in dry mouth (xerostomia), oral discomfort, mucositis, 
recurrent microbial infections, difficulty in chewing and swallowing, increased incidence of 
dental caries, impaired taste, and an inability to wear dentures (Parsons et al., 1994). In 
addition, depression is reported to increase in H&N cancer patients undergoing RT (Neilson 
et al., 2010; Kelly et al., 2007).  
The interest in health-related quality of life (HRQOL) (i.e. the physical, mental, and social 
functioning and well-being) in H&N cancer patients has increased over the two decades (So et 
al., 2012). Even if the most important outcome for cancer patients is overall survival, the 
disease and its treatment often have a major impact on HRQOL and functional status (List et 
al., 2002). Reliable and valid HRQOL questionnaires are available (Aaronson et al., 1993; 
Bjordal et al., 2000; Ringash and Bezjak, 2001). The EORTC QLQ-H&N35 is widely used to 
measure quality of life in H&N cancer patients (Singer et al., 2013). Both prospective and 
cross-sectional studies (Bjordal et al., 2001; Hammerlid et al., 2001a, 2001b, 2001c; Nguyen 
et al., 2002; Talmi et al., 2002; Shepherd and Fisher, 2004) have documented reductions in 
HRQOL in populations of H&N cancer patients who have received RT. Several studies have 
also examined changes in HRQOL during the treatment period (Bjordal et al., 2001; Henson 
et al., 2001; Airolldi et al., 2004; Parliament et al., 2004; Jabbari et al., 2005; Braam et al., 
2007; Curran et al., 2007; Ackerstaff et al., 2009; Ackerstaff et al., 2012; Maguire et al., 2011; 
Maurer et al., 2011; Nutting et al., 2011). These studies show that QOL worsens during 
treatment and improves after cessation of treatment, returning to baseline QOL by 12 months 
after treatment (So et al., 2012; Curran et al., 2007; Bjordal et al., 2001). During the radiation 
treatment period a number of functions and symptoms change significantly, but a direct 
comparison between studies is difficult because of the varying design and HRQOL 
measurements. There are also contradictory findings about the gender influence on QOL 
before and after treatment (So et al., 2012). According to Bjordal et al. (2001) women scored 
lower than men at baseline. Bozec (2008), on the other hand found that women had fewer or 
less severe general and H&N symptoms 12 months after surgery, particularly concerning 
dyspnoea and sticky saliva. de Graeff et al. (2000) found that women scored lower on fatigue, 
pain, physical and emotional functioning and role activities, social contacts and social eating 6 
and 12 months after treatment. Scrimger et al. (2007) who investigated the correlation 
between saliva flow rates and various toxicity endpoints commonly used in H&N cancer 
treatment, demonstrated higher improvement in women than in men from pre-treatment to 12 
months post-treatment, and patients who never had smoked had higher QOL scores before 
and after treatment than ex-smokers and current smokers (Scrimger et al., 2007).  The 
influence of smoking on side effects in H&N cancer patients has rarely been studied (Jensen 
et al., 2007). Ronis et al. (2008) found that smoking was highly predictive of poorer QOL 
scores at 12 months for most items. On the other hand, Aarstad et al. (2007) found no 
significant association between rate of cigarette smoking and levels of general coping in 
patients who had been disease-free for at least 1 year.  
Although many studies have focused on survival rates and QOL in patients with H&N cancer, 
the effort has primarily focused on improving treatment techniques or use of therapies or 
combined modalities (So et al., 2012). To be able to improve supportive care, we need more 
knowledge on factors influencing HRQOL in this vulnerable patient group. This paper 
focuses on the HRQOL and functional status of a representative sample of H&N cancer 
patients from the start to the end of the radiation treatment period. The purpose of the current 
study was twofold. First, the aim was to examine women`s and men’s HRQOL during 
radiation treatment. Secondly, the aim was to examine if smoking status had any impact on 
head and neck cancer patients` HRQOL during radiation treatment.  
Methods 
Study design and participants 
The study was conducted at the University Hospital in Northern Norway, in a period from 
May 2009 to November 2012. All adults patients (18 years or older) with a primary H&N 
cancer, referred to the oncology center for radiotherapy, were consecutively invited to 
participate in the study. When the referral arrived at the department, the chief radiation 
therapist informed the research assistants, all radiation therapists, working in the department. 
The research assistants approached eligible patients, explained the consent and considered 
whether the patients were able to complete the questionnaires and collected the data. Patients 
who were unable to answer the HRQOL questionnaires as a result of mental disturbance, or 
unable to fill the questionnaire for other reasons, or if they were unable to speak and 
understand Norwegian, were excluded. Each eligible patient received a letter broadly 
explaining the purpose and the methods of the study and the level of commitment required to 
participate in the project.  Eighty patients met the criteria and were invited to participate in the 
study.  Three patients refused participation and one relative of a patient declined. Eleven 
patients did not return the written consent. Sixty-five were included, resulting in a recruitment 
rate of 81 %. The study was approved by the Regional Committee for Medical Research 
Ethics (REK NORD 200900504-3KST017/400), and the Norwegian Social Science Data 
Services (21831).  
Data collection 
 Socio demographic and tumor-related patient characteristics were recorded at inclusion, i.e. 
sex, age, residence, tumor location according to ICD-10, TNM (T=tumor size, N=node, M= 
metastasis) and planned treatment was noted. In addition, a study-specific questionnaire was 
filled out by the radiation therapist. The patients also responded to whether they smoked, had 
smoked earlier or stopped smoking after diagnosis.                                                            
HRQOL questionnaires 
Data were collected at two time points: at baseline which was the first radiation treatment 
week; (T1), and in the last week, after 60 Gy; (T2). At T1 and T2, the patients filled in the 
European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 
(Aaronson et al 1993) and EORTC QLQ-H&N35 (Bjordal et al. 2001). The EORTC QLQ-
C30 questionnaire is a generic questionnaire developed for patients with any cancer type. The 
questionnaire is designed for self-administration and assesses multiple dimensions of HRQOL 
and responses to this 30-item questionnaire are categorized into five functional domains 
(physical, role, emotional, cognitive, and social) (scored on a four-point scale), one global 
HRQOL domain (scored on a seven-point scale), three symptom domains (fatigue, 
nausea/vomiting, pain) and six single items (scored on a four-point scale). Each score is 
transformed into 0-100 point scale. EORTC QLQ-H&N35 is a questionnaire specifically 
developed for H&N cancer patients consisting of 35 items on HRQOL. It includes seven 
scales (pain, swallowing, senses, speech, social eating, social contact and sexuality) and 11 
single items (problems with teeth, problems opening the mouth, dry mouth, sticky saliva, 
cough, feeling ill, pain killers, nutritional supplements, feeding tube, weight loss and weight 
gain). Items 1-30 are scored on a four-point scale (1; not at all, 2; a little, 3; quite a bit, 4; very 
much). Items 31-35 have a yes (2) or no (1) response format. Both EORTC instruments were 
scored according to recommendations in the EORTC QLQ-C30 scoring manual (Borggreven 
et al., 2007). In the five functional scales and the global HRQOL scale, a high score 
represents a high level of functioning or global HRQOL. In the symptom scales and single 
items, a higher score implies a high level of symptoms or problems.  
Clinical treatment                                                                                                                                                                               
RT was administered to the primary tumor and the regional neck lymphatics (dependent on N 
stage) by conventional fractionation, i.e. dose of 2 Gy, 1 fraction per day, 5 days per week. 
The total radiation doses were 60-70 Gy. RT was delivered using megavoltage equipment 
(6MV linear accelerator) in general over a period of six to seven weeks. In all patients, 
planning computed tomography scans were used, and all patients were treated with three-
dimensional conformal or intensity-modulated RT. None of the patients had distant 
metastases.  
Statistical analysis 
Baseline characteristics, distribution of tumor location, tumor stage and nodal stage were 
compared between women and men using chi square testing for categorical variables and 
Independent sample T-Tests for continuous variables. The mean scores with the standard 
deviation (SD) of each item are presented at baseline and at the end of the treatment period. 
Differences in scores were calculated by subtraction of scores from baseline to end of 
treatment, and score differences are presented as mean differences (SD). Differences in mean 
score between baseline and end were compared using Paired Sample T-test, and differences in 
scores between the sexes were compared using Independent sample T- tests. To examine if 
factors present at baseline influenced HRQL during the treatment period, linear multiple 
regression analyses were applied using the difference in HRQL score as dependent variable 
and the baseline variables age, body mass index (BMI), smoking status (yes-no), first in 
univariate analyses. The variables which were significant predictors in these analyses, 
including BMI, were included in an initial multivariable model. In the final model only the 
significant variables were included. The significance level was set at P <0.05 using the 
statistical software SPSS 21.0 for Windows. 
Results 
The majority of patients were treated with surgery before they received RT, and 34% were 
treated with cisplatin (chemotherapy) in addition to RT. The majority of the patients received 
RT as 2 Gy-per-fraction, 5 days-a-week to a total dose of 64 to 70 Gy. The baseline 
characteristics of the patients are presented in Table 1. The mean age was 62 (10.5) years in 
men and 53.5 (12.9) years in women (p=0.01). Men were heavier, weighted more than 
women, but BMI and smoking status were not different between the sexes. Dividing the 
tumor locations into four groups (oral cavity, pharynx, larynx, and other), the most common 
sites of primary tumor were the pharynx and the larynx, followed by the oral cavity (Table 2). 
There were 15 men with pharynx, 14 men with larynx and 12 with oral cavity tumors and the 
corresponding tumors in women were five pharynx, one larynx and six oral cavity, 
respectively. Squamous cell carcinoma was evident in 89 % of the participants (data not 
shown).  With regard to the T-stage, 39 (60%) had T1 and T2, 26 (40%) had NO. Lymph 
node status had a similar distribution in both sexes (Table 2).   
At baseline, there were no significant differences between women and men concerning any 
HRQOL item, either in the  EORTC-C30 (Table 3) or the EORTC-QLQ-H&N35 (Table 4) 
(p>0.127) (Independent sample T-Tests). At the end of treatment period, there were still no 
differences between the sexes for any item, except for role functioning (EORTC-C30) where 
women scored lower than men, although the difference was of borderline significance  
(p>0.049) (Table 3) (Independent sample T-Tests). During the treatment period, most item 
scores in the EORTC-C30 declined significantly (Paired Sample T-test), except emotional and 
social function in women (Table 3). In the single item questions of EORTC-C30, there were 
significant changes in the appetite and constipation scores in both genders during the 
treatment period (Table 3), but no significant changes in dyspnea, insomnia and diarrhea 
(Table 3). In the EORTC-QLQ-H&N35, men’s scores for all items deteriorated during 
treatment. Women’s scores worsened for all symptoms except weight gain (which illustrated 
that a minority of patients put on weight during treatment), sexuality, teeth problems and 
coughing (Table 4). The only significant change in scores during treatment between men and 
women was in relation to insomnia, where women`s scores changed more than men`s 
(p=0.012) (symptom score QLQ-C30) (Independent sample T-Tests). Pain scores also tended 
to increase more in women compared to men (p=0.053) (specific QLQ-H&N35). When 
adjusting for age, these changes were however no longer significantly different, insomnia; 
p=0.332 and pain; p=0.834. The only item that was significantly different between the sexes 
after age adjustment was self-reported weight loss which was more frequently reported by 
women (p=0.024).  
Because of the similar changes in HRQOL in women and men during the treatment period, 
we did not stratify or adjust for sex in further analyses. In bivariate regression analyses, there 
was a significant association between age and changes in the EORTC QLQ H&N35 single 
item open mouth (p=0.024) (Table 5). BMI was not associated with any item, but smoking 
status was associated with use of pain killers (p=0.043) (specific QLQ H&N35) and was of 
borderline significance for social eating (p=0.055) (specific QLQ H&N35) (Table 5). 
The variables which were significant predictors in the bivariate analyses (smoking status and 
age) were used as independent variables and the differences in HRQL scores as dependent 
variables in further multivariable modelling. The final models indicated that smoking status 
was associated with increased fatigue (p= 0.027), pain (p=0.009) (symptom score QLQ-C30), 
speech (p=0.017) (specific QLQ-H&N35) and maximum mouth opening (single-item QLQ-
H&N35) (Table 5). In addition, smoking status was also associated with poorer cognitive 
function (p=0.041). Age was furthermore negatively associated with pain (p=0.042) 
(symptom score QLQ-C30), maximum mouth opening (p= 0.006) and use of feeding tube 
(p=0.046) (single-item QLQH&N35).  
Discussion 
In the present study we evaluated changes in HRQOL and examined if factors present at 
baseline modified these changes during radiation treatment in a population of 65 H&N cancer 
patients. Most aspects of HRQOL declined significantly during the radiation treatment period 
in both sexes, a finding which is in accordance with other studies (Bjordal et al., 2001; Curran 
et al., 2007; Airoldi al., 2004; Braam et al., 2007; Ackerstaff et al., 2009; Ackerstaff et al., 
2012; Shepherd and Fisher, 2004). In principle, there were no differences in reported HRQOL 
between the sexes at baseline and at the end of the treatment period, except that at the end of 
the treatment period women scored lower than men in role functioning, as also reported by de 
Graeff et al.(2000). This result can possibly be related to the fact that women in our study 
were younger (mean age 53.5 years) than men and thereby may have been more affected in 
their role functioning.  
Among factors present at baseline, smoking status had some impact on changes in HRQOL. 
Patients who continued smoking through the intervention period had poorer QOL compared 
to never smokers and those who quitted smoking. To our knowledge, this is the first study to 
demonstrate a relationship between continued smoking and QOL during the radiation 
treatment period. Continued smoking was associated with higher decline in several aspects of 
HRQOL, except for cognitive function, where smokers had better QOL than patients who did 
not smoke. This finding can be seen in the context of the fact that nicotine may improve 
performance in relation to attention and memory (Rezvani and Levin 2001). Former smokers 
who had stopped smoking before radiation treatment, reported better HRQOL, and the lowest 
HRQOL deterioration was found in patients who never had smoked. This result was also 
reflected in the study by Jensen et al. (2007) who found that smoking after radiotherapy or 
surgery in H&N cancer patients adversely influenced a wide range of QOL endpoints. In their 
study, quitters had better HRQOL than patients who continued to smoke after treatment, and 
previous smokers` HRQOL scores fell between those of never smokers and continuous 
smokers (Jensen et al., 2007). The link between tobacco smoking and H&N cancer has been 
highlighted by others: Smoking during RT can reduce its efficacy (Meyer et al., 2008; 
Browman et al., 1993) and Edwards (2004), and Browman et al. (2002) showed better 
survival in light smokers compared to moderate and heavy smokers. Humphris and Rogers 
(2004) examined the association of smoking and anxiety in oral cancer patients after treatment 
and found that past and current smoking behaviour was associated with psychological distress 
(Humphris and Rogers 2004). Ronis et al. (2008) focused on QOL in patients with head and 
neck cancer shortly before treatment and found that smoking was a major predictor of poor 
QOL. Aarstad et al. (2007) found significant correlations between the number of cigarettes 
smoked per week and QOL in head and neck cancer after treatment. During radiation 
treatment a significant correlation was shown with smoking and the volume of mucosa 
irradiated (Rugg et al., 1990) and smoking increased the severity of mucositis and acute skin 
reactions (Porock et al., 2004).  Wells et al (2004) found that head and neck cancer patients 
who continued smoking during RT were more likely to develop skin reactions than former 
smokers and non-smokers. Non-smokers had lower skin toxicity scores (Wells et al. 2004). 
Sharp et al. (2013) examined risk factors for severe acute radiation skin reactions in women 
undergoing RT for breast cancer. Radiation dose and smoking were the factors most strongly 
related to severe acute skin reactions (Sharp et al. 2013). Duffy et al. (2002) who used a QOL 
questionnaire SF-36V (Ware et al., 1994) on 81 head and neck cancer patients found that 
smoking was negatively associated with physical and social functioning, general health, 
vitality, and role-emotional health. Although different in design and measurements, these 
findings are all comparable with ours. 
The data presented here, illustrate how a number of functions and symptoms change 
significantly during the radiation treatment period, particularly influencing mouth opening, 
speech problems, pain, fatigue, use of feeding tube and use of pain killers. Changes in 
HRQOL were also analyzed with regard to the background variables sex, age and BMI. Sex 
did not influence the observed changes in HRQOL in this population, but older patients 
reported more pain, more use of pain killers and more problems with mouth opening. Sex was 
not a significant factor in a study by de Graeff et al. (2000), but age had an influence on 
fatigue, physical functioning, social eating, and speech; as older patients had worse scores. 
Williamson et al. (2011) found no evidence of an age effect when they evaluated HRQOL of 
patients with head and neck cancer, but they did not include sex analyses in their study. 
HRQOL was associated with patients’ age in Lòpez-Jornets et al. study (2012), who evaluated 
94 patients undergoing treatment for head and neck cancer in Spain. In their study females 
had a slight tendency to score worse than males for some functioning scales with symptoms, 
financial difficulty and sexuality. Hammerlid et al. (2001a) found that females scored worse 
than males for some areas at diagnosis, in particular, in emotional functioning. These 
conflicting results on gender differences cannot easily be explained, but overall, gender does 
not seem to have a major influence on HRQL during radiation treatment – the decline seems 
to be similar in the two sexes.  
There are strengths and weaknesses to be discussed in the present study. The socio-
demographic characteristics of the sample are representative of head and neck populations 
with a preponderance of men (75.4%). Among eligible patients, 81% agreed to participate in 
the study. The study cohort is therefore likely to be a representative sample of this patient 
group. A weakness of the study is that we did not examine the participants` physical 
condition, nutrition status and morbidity at baseline. We were not able to repeat the 
examination during the treatment period, so we do not know when the decline in HRQOL 
started.  It is also a limitation to our study that we were not able to follow the cohort after 
cessation of treatment. Therefore, we do not know if HRQOL improved after the end of 
treatment. What we know is that the 5-year survival rate of these patients is 65.9% (Pulte and 
Brenner, 2010) and that HRQOL declines substantially during RT. The sample size should 
have been larger particularly for the regression analysis therefore our findings must be 
interpreted with caution. Another weakness in this study is that patients who said they had 
given up smoking may in fact still be smokers. According to Hald et al. (2003), recent quitters 
may under-report their current smoking status. Furthermore, we do not know the length of 
nicotine abstinence in this population. However, all data were collected in structured 
interviews and all patients answered the questions about tobacco use with a research assistant 
present.  
Implications for practice include the need for health care providers to be aware of the impact 
that continued smoking during RT has on patients HRQOL. Before treatment starts, patients 
should be advised that continued smoking is associated with greater decline in quality of life. 
Radiation therapists and nurses should provide smoking cessation support prior to, during and 
at the end of the 5-7 week RT treatment period. Psychological support during treatment is 
important for all patients but perhaps more for smokers trying to quit as there is an emotional 




HRQOL is severely affected during treatment for head and neck cancer patients, independent 
of patients` gender, age and BMI. In this study, smoking status at baseline was the only factor 
which seemed to influence the magnitude of HRQOL loss.  Head and neck cancer patients 
who quit smoking before treatment may reduce the decline in their quality of life.Radiation 
therapists and nurses should therefore provide greater levels of smoking cessation support to 
patients before they start their treatment.   
 
Conflicts of interest 
The authors have no funding or conflicts of interest to disclose. 
 
Acknowledgement 
We thank all the patients who allowed us to follow them with these questionnaires during a 
difficult time of their lives. Thanks also to the radiation staff and Dr. Nieder who supported 




Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, J., Filiberti, A., Flechtner, H., 
Fleishman, S.B., de Haes, J.C.J.M., Kaasa, S., Klee, M., Osobam D., Razavi, D., Rofe, P.B., Schraub, S., 
Sneeuw, K., Sullivan, M., Takeda, F., 1993.  The European Organization for Research and Treatment of Cancer 
QLQ-C30: a quality-of-life instrument for use in international clinical trials on oncology. Journal of the National 
Cancer Institute  85, 365-376. 
Aarstad A.K., Aarstad H.J., Olofsson J., 2007. Quality of life, drinking to cope, alcohol consumption and 
smoking in successfully treated HNSCC patients. Acta Oto-Laryngologica 127, 1091-1098. 
Ackerstaff A., Rasch C.R.N., Balm J.M., de Boer J.P., Wiggenraad R., Rietveld D.H.F., Gregor R.T., Kröger R., 
Hauptmann M., Vincent A., 2012. Five-years quality of life results of the randomized clinical phase III 
(RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally 
advanced head and neck cancer. Head and Neck 34 (7), 974-980. 
Ackerstaff A., Balm J.M, Rasch C.R.N.,  de Boer J.P., Wiggenraad R., Rietveld D.H.F., Gregor R.T., Kröger R., 
Hilgers J.M., 2009. First year quality of life assessment of an intra-artrial (RADPLAT) versus intravenous 
chemoradiotherapy phase III trial. Head and Neck 31 (1),77-84.   
Airoldi M., Corstesina G., Giordano C., Pedani F., Gabriele A.M., Marchionatti S., Bumma C., 2004. 
Postoperative adjuvant chemoradiotherapy in older patients with head and neck cancer. Arch Otolaryngol head 
and neck surgery 130, 161-166.  
Archer, J., Hutchison, I. and Korszun, A., 2008. Mood and malignancy: head and neck cancer and depression. 
Journal of Oral and Pathology & Medicine  37, 255-270.  
Bjordal, K., de Graeff, A., Fayers, P.M., Hammerlid, E., van Pottelsberghe, C., Curran, D., Ahlner- Elmqvist, 
M., Maher, E.J., Meyza, J.W., Brèdart, A., Söderholm, A.L., Arraras, J.J., Feine, J.S., Abendstein, H., Morton, 
R.P., Pignon, T., Huguenin, P., Bottomly, A., Kaasa, S., 2000. A 12 country field study of the EORTC QLQ-C30 
(version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. 
European Journal of Cancer 36, 1796-1807. 
Bjordal, K., Ahlner-Elmqvist, M., Hammerlid, E., Boysen, M., Evensen, J.F., Björklund, A., Jannert, M., Westin, 
T., Kaasa, S., 2001. A prospective study of quality of life in head and neck cancer patients. Part II: longitudinal 
data. Laryngoscope  111(8), 1440-52.  
Borggreven, P.A., Verdonck-de Leeuw, I.M., Muller,M., Heiligers, L.C.H., de Bree, R., Aaronson, N.K., 
Leemans, C.R., 2007. Quality of life and functional status in patients with cancer of the oral cavity and 
oropharynx: pretreatment values of a prospective study. European Archives Otorhinolaryngol 264,651-657.  
Bozec A., Poissonnet G., Chamorey E., Casanova C., Vallicioni J., Demard F., Mahdyoun P., Peyrade F., 
Follana P., Bensadoun R-J., Benezery K., Thariat J., Marcy P-Y., Sudaka A., Dassonville O. 2008. Free-flap 
head and neck reconstruction and quality of life: a 2-year prospective study. The Laryngoscope 118, 874-880. 
Braam P.M., Roesink J.M., Raaijmakers C.PJ., Busschers W.B., Terhaard C HJ., 2007. Quality of life and 
salivary output in patients with head-and-neck cancer five years after radiotherapy. Radiation Oncology 2:3 
doi:10.1186/1748-717-2-3. 
Browman, G.P., Wong G., Hodson, I.,1993. Influence of cigarette smoking on the efficacy of radiation therapy 
in head and neck cancer. The New England Journal of Medicine 328, 159-163. 
Browman, G.P., Mohide, A., Willan, A., Hodson, I., Wong, G., Grimard, L., MacKenzie, R.G., El-Sayed, S., 
Dunn, E., Farrell, S., 2002. Association between smoking during radiotherapy and prognosis in head and neck 
cancer: a follow-up study. Head & Neck  24,1031-1037. 
Curran D., Giralt J., Harari P.M., Ang K.K., Cohen B., Kies M.S., Jassem J., Baselga J., Rowinsky E.K., 
Amellah N., Comte S., Bonner J.A., 2007. Quality of life in head and neck cancer patients after treatment with 
high-dose radiotherapy alone or in combination with cetuximab. Journal of Clinical Oncology 25,16, 2191-2197. 
de Graeff, A., de Leeuw, R.J., Ros, W.J.G., Hordijk, G-J., Blijham, G.H., Winnubst, J.A.M., 2000. Pretreatment 
factors predicting quality of life after treatment for head and neck cancer. Head & Neck 22,398-407. 
Duffy, S.A., Terrell, J.E., Valenstein, M., Ronis, D.L., Copeland, L.A., Connors, M., 2002. Effect of smoking, 
alcohol, and depression on the quality of life of head and neck cancer patients. General Hospital Psychiatry 
24,140-147. 
Edwards, R., 2004. The problem of tobacco smoking. British Medical Journal 328, 217-219. 
Hald J., Overgaard J., Grau C., 2003. Evaluation of objective measures of smoking status – a prospective clinical 
study in a group of head and neck cancer patients treated with radiotherapy. Acta Oncologica 42,154-159. 
Hammerlid, E., Bjordal, K., Ahlner-Elmqvist, M., Boysen, M., Evensen, J.F., Björklund, A., Jannert, M., Kaasa, 
S., Sullivan, M., Westin, T., 2001a. A prospective study of quality of life in head and neck cancer patients. Part 
1: At diagnosis. The Laryngoscope 111, 669-680. 
Hammerlid, E., Silander, E., Hornestam, L., Sullivan, M., 2001b. Health-related quality of life three years after 
diagnosis of head and neck cancer – a longitudinal study. Head Neck  23, 113-125. 
Hammerlid, E., C.,2001c. Health-related quality of life in long-term head and neck cancer survivors: A 
comparison with general population norms. British Journal of  Cancer  84,149-156. 
Henson  B.S., Inglehart M.R., Eisbruch A., Ship J.A., 2001. Preserved salivary output and xerostomia-related 
quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncology 37, 84-93. 
Humphris G.M., Rogers S.N., 2004. The association of cigarette smoking and anxiety, depression and fears of 
recurrence in patients following treatment of oral and oropharyngeal malignancy. European Journal of Cancer 
Care 13, 328-335. 
Jabbari S., Kim H.M., Feng M., Lin A., Tsien C., Elshaikh M., Eisbruch A., 2005. Matched case-control study of 
quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head and neck 
cancer: initial report. International Journal of Radiation Oncology Biology Phys 63, 3, 725-731. 
 
Jensen, K., Jensen, A.B., Grau, C., 2007. Smoking has a negative impact upon health related quality of life after 
treatment for head and neck cancer, Oral Oncology 43, 187-192.  
Kelly C., Paleri V., Downs C., Shah R., 2007. Deterioration in quality of life and depressive symptoms during 
radiation therapy for head and neck cancer. Otolaryngol Head Neck Surgery 136, 108-111. 
Larsson, M., Hedelin, B., 2003. Lived experiences of eating problems for patients with head and neck cancer 
during radiotherapy. Journal of Clinical Nursing 12(4), 562-570. 
List, M.A., Rutherford, J., Stracks, J., Haraf, D., Kies, MS., Vokes, EE., 2002. An exploration of the 
pretreatment coping strategies of patients with carcinoma of the head and neck. Cancer 95,98-104. 
Lòpez-Jornet, P., Camacho-Alonso, F., Lòpez- Tortosa, J.,Tovar, T.P., Rodrìguez-Gonzales, M.A., 
2012.Assessing quality of life in patients with head and neck cancer in Spain by means of EORTC QLQ-C30 
and QLQ-H&N35. Journal of Cranio-Maxillo-Facial Surgery 40 (7), 614-620. 
Maguire P., Papagikos M., Hamann S., Neal C., Meyerson M., Hayes N., Ungaro P., Kotz K., Couch M., Pollock 
H., Tepper J., 2011. Phase II trial of hyperfractionated IMRT and Concurrent weekly cisplatin for stage III and 
Iva head and neck cancer. National Institute of Health 79 (4), 1081-1088. 
Maurer J., Hipp M., Schäfer C., Kölbl O., 2011. Dysphagia impact on quality of life after radio(chemo)therapy 
of head and neck cancer. Strahlentherapie und Onkologie 11, 744-749. 
Meyer, F., Bairati, I., Fortin, A.,Gèlinas, M., Nabid, A., Brochet, F., Têtu, B., 2008. Interaction between 
antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term 
effects on recurrence and mortality: A randomized trial among head and neck cancer patients. International 
Journal Cancer 122, 1679-1683. 
Neilson K.A., Pollard A.C., Boonzaier A.M., Corry, J., Castle, D.J., Mead, K.R., Gray, M.C., Smith, D.I., 
Trauer, T., Couper, J.W., 2010. Psychological distress (depression and anxiety) in people with head and neck 
cancers. Medical Journal of  Australia 193, S48-S51. 
Nguyen, N.P., Sallah, S., Karlsson, U., Antoine, J.E., 2002. Combined chemotherapy and radiation therapy for 
head and neck malignancies. Cancer  94,1131-1141. 
Nutting C.M., Morden J.P., Harrington K., Urbano T.G., Bhide S., Clark C., Miles E.A., Miah A., Newbold K., 
Tanay M.A., Adab F., Jefferies S., Scase C., Yap B.K., A`Hern R.P., Sydenham M.A., Emson M., Hall E., 2011. 
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a 
phase 3 multicentre randomized controlled trial. Lancet Oncology 12, 127-136. 
Parliament M.B., Scrimger R.A., Anderson S.G., Kurien E.C., Thompson H.K., Field G.C., Hanson J., 2004. 
Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity-
modulated radiotherapy (IMRT) for head and neck cancer. International Journal of  Radiation Oncology Biology 
Physics 58, 3, 663-673. 
Parsons J.T., 1994. The effect of radiation on normal tissues of the head and neck. In: Million R.R., Cassisi N.J., 
editors. Management of head and neck cancer. A multidisciplinary approach. 2nd ed.Philadelphia, PA: J.B. 
Lippincott Co, p.245-89. 
Porock, D., Nikoletti, S., Camaron, F., 2004. The relationship between factors that impair wound healing and the 
severity of acute radiation skin and mucosal toxicities in head and neck cancer. Cancer Nursing 27(1), 71-78.  
Pulte, D., Brenner, H.,2010.  Changes in survival in head and neck cancers in the late 20 th and early 21st century: 
a period analysis. The Oncologist 15(9), 994-1001. 
Rezvani A.H., Levin E.D., 2001. Cognitive effects of nicotine. Biological Psychiatry 49, 258-267. 
Ringash, J., Bezjak, A., 2001. A structured review of quality of life instruments for head and neck cancer 
patients. Head Neck 23, 201-213. 
Ronis D.L., Duffy S.A., Fowler K.E., Khan M.J., Terrell J.E., 2008. Changes in quality of life over 1 year in 
patients with head and neck cancer. Arch Otolaryngol head and neck surgery 134,3, 241-248. 
Rugg, T., Sauders, M.I., Dische, S., 1990. Smoking and mucosal reactions to radiotherapy. The British Journal 
of Radiology 63, 554-556. 
Scrimger R., Kanji A., Parliament M., Warkentin H., Field C., Jha N., Hanson J., 2007. Correlation between 
salvia production and quality of life measurements in head and neck cancer patients treated with intensity-
modulated radiotherapy. American Journal of Clinical Oncology 30,3, 271- 277.  
Sharp L., Johansson H., Hatschek T., Bergenmar M., 2013. Smoking as an independent risk factor for severe 
skin reactions due to adjuvant radiotherapy for breast cancer. The Breast 22, 634-638. 
Shepherd, K.L., Fisher, S.E., 2004. Prospective evaluation of quality of life in patients with oral and 
oropharyngeal cancer: from diagnosis to three mouths post-treatment. Oral Oncology 40, 751-757. 
Singer S., Arraras J.I., Chie W-C., Fisher S.E., Galalae R., Hammerlid E., Nicolatou-Galitis O., Schmalz C., 
Verdonck-de Leeuw I., Gamper E., Jeszte J., Hofmeister D., 2013. Performance of the EORTC questionnaire for 
the assessment of quality of life in head and neck cancer patients EORTC QLQ-H&N35: a methodological 
review. Quality of Life Research 22 (8), 1927-41.  
So, W.K.W.,2012. Quality-of-life among head and neck cancer survivors at one year after treatment – A 
systematic review. European Journal of Cancer 48, 2391-2408. 
Talmi, Y.P., Horowitz, Z., Bedrin, L., Wolf, M., Chaushu, G., Kronenberg, J., Pfeffer, M.R.,2002. Quality of life 
of nasopharyngeal carcinoma patients. Cancer 94, 1012-1017. 
Ware, J.E., Kosinski, M., Keller, S.D.,1994. SF-36 Physical and Mental Summary Scales: a user’s manual, The 
Health Institute, Boston, MA. 
Wells, M.,1998. The hidden experience of radiotherapy to the head and neck: a qualitive study of patients after 
completion of treatment. Journal of Advanced Nursing 28(4), 840-848. 
Wells M., Macmillan M., Raab G., MacBride S., Bell N., MacKinnon K., MacDougall H., Samuel L., Munro 
A.,2004. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A 
randomized controlled trial. Radiotherapy and Oncology, 73, 153.162.    
Williamson, J.S., Ingrams, .D, Jones, H.,2011. Quality of life after treatment of laryngeal carcinoma: a single 
centre cross-sectional study.  Head & Neck  93, 591-59 
 
Table 1 Patient characteristics at baseline (n=65) 
Characteristics Women (n=16) Men (n=49) P-value 
Age (years)  mean (SD) 53.5 (12.9) 62 (10.5) 0.010 
Height (cm) mean (SD) 164.3 (6.7) 178.8 (6.8) <0.001 
Weight (kg) mean (SD) 67.2 (13.9) 83.1(12.2) <0.001 
BMI (kg/m2) mean (SD) 1.6 (5.6) 1.4 (5.7) 0.287 
Smoker (n/%) 4 (25%) 9 (18%) 0.559 
Never smoker 5 (31%) 11(22%)  
Former smoker 7 (44%) 29 (60%)  
 
 
Table 2 Pretreatment characteristics of the study cohort (n=65) 
Characteristics Women % (n) Men % (n) 
Tumor location   
Oral cavity 37.5 (6) 24.5 (12) 
Pharynx        31.2 (5) 30.6 (15) 
Larynx 6.3 (1) 28.6 (14) 
Others/unknown 25.0 (4) 16.3 (8) 
T-stage   
T1 56.3 (9) 22.4 (11) 
T2 12.5 (2) 34.7 (17) 
T3 12.5 (2) 12.2 (6) 
T4 6.3 (1) 14.3 (7) 
Tx   4.1 (2) 
Not stated 12.5 (2) 12.2 (6) 
N-stage   
N0 43.8 (7) 38.8 (19) 
N1 25.0 (4) 26.5 (13) 
N2 12.5 (2) 18.4 (9) 
Not stated 18.7 (3) 16.3 (8) 
 
Table 3 Development in quality of life (EORTC-C30) from baseline to end of treatment 









Physical functioning     
Men 82.8 (17.2) (n=48) 68.2(24.6) (n=44) 15,9;20,2 0.000 
Women  83.3(13.5) (n=14) 65.0(19.1) (n=12) 20,6;21,2 0.006 
Role functioning     
Men  73.6(27.5) (n=48) 48.3(34.6) (n=40) 26,5;31,7 0.000 
Women  65.5(22.1) (n=14) 26.4(27.0) (n=12) 43,1;20,7 0.000 
Emotional functioning     
Men  84.3(19.1) (n=48) 74.4(24.0) (n=44) 10,1;27,6 0.021 
Women  75.6(27.0) (n=14) 77.1(20.8) (n=12) -1,4;24,1 0.845 
Cognitive functioning     
Men  86.8(19.4) (n=48) 74.1(26.5) (n=44) 13,4;23,2 0.000 
Women  84.5(20.1) (n=14) 65.3(36.6) (n=12) 20,8;31,9 0.045 
Social functioning     
Men  73.6(27.3) (n=48) 62.7(31.0) (n=42) 10,6;20,3 0.002 
Women  65.5(30.3) (n=14) 48.6(34.4) (n=12) 20,8;46,1 0.146 
Global health scale     
Men  67.7(20.4) (n=48) 48.3(25.8) (n=44) 20,3;20,3 0.000 
Women  61.3(29.5) (n=14) 45.1( 21.7) (n=12) 22,9;29,5 0.021 
Symptom scale     
Fatique     
Men  32.2(22.4)(n=48) 56.6(27.8) (n=44) -24,8;23,0 0.000 
Women  38.9(28.8) (n=14) 61.1(29.8) (n=12) -25,9;31,5 0.016 
Nausea and vomiting     
Men  14.1(23.1) (n=48) 29.9(30.6) (n=44) -14,9;33,2 0.005 
Women  17.9(21.1) (n=14) 34.7(29.7) (n=12) -20,8;23,7 0.011 
Pain     
Men  16.7(21.2) (n=48) 49.2(32.5) (n=44) -33,3;28,4 0.000 
Women  21.4(20.1) (n=14) 52.8(34.7) (n=12) -34,7;38,6 0.010 
Single-item question     
Dyspnoea     
Men  23.6(24.8) (n=48) 29.5(28.0) (n=44) -6,2;24,4 0.103 
Women  14.3(21.5) (n=14) 19.4(22.3) (n=12) -11,1;21,7 0.104 
Insomnia     
Men  27.8(29.4) (n=48) 32.6(31.7) (n=44) -4,6;25,8 0.243 
Women  42.9(40.1) (n=14) 25.0(25.1) (n=12) 19,4;36,1 0.089 
Loss of appetite     
Men  19.4(31.4) (n=48) 63.6(36.5) (n=44) -43,4;36,8 0.000 
Women  33.3(39.2) (n=14) 60.6(32.7) (n=11) -33,3;36,5 0.013 
Constipation     
Men  20.1(23.6) (n=48) 46.2(38.2) (n=44) -27,9;44,2 0.000 
Women  20.5(34.8) (n=13) 50.0(41.4) (n=12) -39,4;44,3 0.014 
Diarrhea     
Men  17.0(24.9) (n=47) 18.2(28.3) (n=44) 0.0;32,9 1.0 
Women  9.5(20.4) (n=14) 9.1(15.6) (n=11) 3,0;18,0 0.588 
Financial difficulty     
Men  18.1(30.7) (n=48) 25.0(32.2) (n=44) -6,2;31,9 0.210 















Table 4 Development in quality of life (EORTC-QLQ-H&N35) from baseline to end of treatment in 





End Mean (SD) Mean difference 
(SD)  
P-value  
Pain     
Men  18.7 (17.1) (n=49) 47.0(27.4) (n=44) -29,2;24,2 0.000 
Women  19.0(14.4) (n=14) 62.5(24.2) (n=12) -45,1;27,2 0.000 
Swallowing     
Men  10.8(14.7) (n=49) 45.7(28.3) (n=43) -34,2;31,5 0.000 
Women  8.3( 16.0) (n=14) 43.7(33.5) (n=12) -40,3;34,1 0.002 
Senses     
Men  21.1(29.6) (n=49) 51.9(31.4) (n=44) -31,4;32,0 0.000 
Women  21.4(20.1) (n=14) 56.9(25.1) (n=12) -38,9;27,8 0.001 
Speech     
Men  19.7(18.9) (n=49) 45.3(29.5) (n=43) -24,7;28,7 0.000 
Women  11.9(23.7) (n=14) 37.0(24.3) (n=12) -30,6;20,2 0.000 
Social eating     
Men  16.1(20.5) (n=49) 49.8(28.0) (n=43) -35,1;30,3 0.000 
Women  16.1(21.3) (n=14) 50.8(24.3) (n=11) -39,4;18,3 0.000 
Social contact     
Men  4.7(8.0) (n=48) 23.9(26.8) (n=41) -19,0;26,5 0.000 
Women  6.7(11.4) (n=14) 32.7(26.1) (n=11) -24,8;20,5 0.002 
Sexuality     
Men  29.3(30.6)(n=44) 47.7(32.2) (n=37) -23,0;38,9 0.002 
Women  43.9(34.4) (n=11) 60.7(40.4) (n=10) -16,7;41,8 0.296 
Single-item questions     
Teeth     
Men  10.6(25.2) (n=47) 18.3(29.6) (n=42) -8,9;23,6 0.020 
Women  2.4( 8.9) (n=14) 25.6(13.0) (n=12) -2,8;9,6 0.339 
Dry mouth     
Men  37.4(30.9) (n=49) 65.9(30.4) (n=43) -28,7;30,5 0.000 
Women  38.1(31.6) (n=14) 63.9(33.2) (n=12) -30,6;36,1 0.014 
Sticky saliva     
Men  33.3(30.9) (n=48) 69.8(31.9) (n=42) -37,3;33,1 0.000 
Women  31.0(27.6) (n=14) 75.0(32.2) (n=12) -50,0;33,3 0.000 
Coughing     
Men  23.8(20.4) (n=49) 43.4(29.6) (n=43) -19,4;26,5 0.000 
Women  19.0(28.4) (n=14) 27.8(23.9) (n=12) -13,9;30,0 0.137 
Maximum mouth 
opening 
    
Men  19.7(27.1) (n=49) 41.1(35.5) (n=43) -20,9;33,4 0.000 
Women  11.9(28.1) (n=14) 47.2(33.2) (n=12) -33,3;34,8 0.007 
Weight loss     
Men  24.5(43.4) (n=49) 61.9(49.2) (n=42) -40,5;49,7 0.000 
Women  15.4(37.6) (n=13) 75.0(45.2) (n=12) 66,7;49,2 0.001 
Weight gain     
Men  38.3(49.1) (n=47) 5.0(22.1) (n=40) 33,4;53,0 0.000 
Women  23.1(43.9) (n=13) 9.1(30.2) (n=11) 18,2;60,3 0.341 
Use of nutritional 
supplements 
    
Men  22.4(4.,2) (n=49) 60.5(49.5) (n=43) -39,5;49,5 0.000 
Women  15.4(37.6) (n=13) 50.0(52.2) (n=12) -45,5;52,2 0.016 
Use of feeding tube     
Men  4.3(20.4) (n=47) 37.2(48.9) (n=43) -16,3;57,4 0.000 
Women  7.1(26.7) (n=14) 50.0(52.2) (n=12) -45,5;52,2 0.007 
Use of pain killers     
Men  42.9(50.0) (n=49) 93.0(25.8) (n=43) -48,8;50,6 0.000 
Women  57.1(51.4) (n=14) 83.3(38.9) (n=12) -33,3;49,2 0.039 
Feeling ill     
Men  17.9(22.9) (n=49) 45.2(29.3) (n=42) -29,1;28,7 0.000 




Table 5 The effect of age, body mass index (BMI) and smoking on HQRL changes in patients undergoing 
radiation therapy 
 
 Univariate regression analyses Multivariate regression analyses 
HRQL Age BMI Smoking Age BMI Smoking 
EORTC QLQ-
C30 
p-value p-value p-value p-value p-value p-value 
Functional scales       
Physical diff 0.383 0.112 0.083 0.728 0.072 0.116 
Role diff 0.691 0.358 0.668 0.421 0.320 0.424 
Emotional diff 0.186 0.484 0.677 0.292 0.454 0.735 
Cognitive diff 0.580 0.170 0.125 0.155 0.100 0.041 
Social diff 0.252 0.658 0.273 0.245 0.738 0.361 
Global health diff 0.529 0.615 0.655 0.354 0.678 0.474 
Symptom scale       
Fatique 0.912 0.117 0.074 0.411 0.061 0.027 
Nausea and 
vomiting 
0.663 0.431 0.511 0.333 0.530 0.195 
Pain 0.293 0.611 0.060 0.042 0.390 0.009 
Dyspnoea 0.569 0.327 0.852 0.748 0.333 0.935 
Insomnia 0.903 0.406 0.655 0.721 0.466 0.502 
Loss of appetite 0.896 0.486 0.265 0.647 0.588 0.276 
Constipation 0.690 0.913 0.985 0.698 0.846 0.588 
Diarrhea 0.151 0.855 0.303 0.157 0.804 0.767 
Financial difficulty 0.679 0.468 0.411 0.448 0.404 0.332 
EORTC QLQ-
H&N35 
      
Pain 0.644 0.920 0.445 0.429 0.828 0.336 
Swallowing 0.181 0.313 0.080 0.057 0.410 0.080 
Senses 0.967 0.537 0.748 0.996 0.559 0.891 
Speech 0.301 0.911 0.078 0.067 0.674 0.017 
Social eating 0.758 0.603 0.055 0.340 0.782 0.064 
Social contact 0.192 0.397 0.250 0.099 0.308 0.137 
Sexuality 0.492 0.318 0.505 0.242 0.212 0.204 
Single-item 
questions 
      
Teeth 0.878 0.617 0.217 0.749 0.528 0.231 
Dry mouth 0.452 0.174 0.101 0.773 0.228 0.254 
Sticky saliva 0.363 0.587 0.076 0.598 0.698 0.216 
Cough 0.675 0.213 0.412 0.379 0.157 0.149 
Maximum mouth 
opening 
0.024 0.799 0.356 0.006 0.608 0.049 
Weight loss 0.170 0.517 0.951 0.255 0.513 0.926 
Weight gain 0.833 0.506 0.666 0.887 0.513 0.969 
Use of nutritional 
supplements 
0.763 0.204 0.145 0.761 0.408 0.079 
Use of feeding tube 0.213 0.658 0.176 0.046 0.920 0.058 
Use of pain killers 0.490 0.901 0.043 0.154 0.673 0.021 
Feeling ill 0.267 0.998 0.846 0.142 0.967 0.690 
 
 
 
 
